As of 2025-03-22, the EV/EBITDA ratio of Y-mAbs Therapeutics, Inc (YMAB) is -5.59. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. YMAB's latest enterprise value is 155.25 mil USD. YMAB's TTM EBITDA according to its financial statements is -27.75 mil USD. Dividing these 2 quantities gives us the above YMAB EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.1x - 14.9x | 13.5x |
| Forward P/E multiples | 21.7x - 48.3x | 35.0x |
| Fair Price | (11.83) - (7.66) | (13.40) |
| Upside | -340.5% - -255.7% | -372.3% |
| Date | EV/EBITDA |
| 2025-03-17 | -5.33 |
| 2025-03-14 | -5.19 |
| 2025-03-13 | -5.28 |
| 2025-03-12 | -5.58 |
| 2025-03-11 | -5.63 |
| 2025-03-10 | -5.33 |
| 2025-03-07 | -5.98 |
| 2025-03-06 | -6.13 |
| 2025-03-05 | -5.48 |
| 2025-03-04 | -5.66 |
| 2025-03-03 | -6.03 |
| 2025-02-28 | -6.64 |
| 2025-02-27 | -6.41 |
| 2025-02-26 | -6.56 |
| 2025-02-25 | -6.67 |
| 2025-02-24 | -6.85 |
| 2025-02-21 | -6.90 |
| 2025-02-20 | -7.42 |
| 2025-02-19 | -8.04 |
| 2025-02-18 | -7.68 |
| 2025-02-14 | -7.74 |
| 2025-02-13 | -7.63 |
| 2025-02-12 | -7.24 |
| 2025-02-11 | -6.98 |
| 2025-02-10 | -7.60 |
| 2025-02-07 | -7.40 |
| 2025-02-06 | -7.63 |
| 2025-02-05 | -7.70 |
| 2025-02-04 | -7.35 |
| 2025-02-03 | -7.03 |
| 2025-01-31 | -7.30 |
| 2025-01-30 | -7.66 |
| 2025-01-29 | -7.60 |
| 2025-01-28 | -7.50 |
| 2025-01-27 | -7.60 |
| 2025-01-24 | -7.76 |
| 2025-01-23 | -7.81 |
| 2025-01-22 | -7.66 |
| 2025-01-21 | -7.66 |
| 2025-01-17 | -7.61 |
| 2025-01-16 | -7.65 |
| 2025-01-15 | -7.99 |
| 2025-01-14 | -7.89 |
| 2025-01-13 | -8.17 |
| 2025-01-10 | -8.80 |
| 2025-01-08 | -9.62 |
| 2025-01-07 | -10.04 |
| 2025-01-06 | -10.30 |
| 2025-01-03 | -10.89 |
| 2025-01-02 | -10.56 |